Clinical Trial Update: Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating the combination of sorafenib with TACE in hepatocellular carcinoma guided by GALNT14 genotype.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• TACE

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Hepatocellular Carcinoma | Phase 4 | Status: UNKNOWN